Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure.
A diabetic patient with chronic renal failure who developed recurrent and prolonged episodes of hypoglycemia associated with use of sulfonylurea agent is presented here. This patient was hospitalized with neuroglycopenic symptoms of hypoglycemia that persisted in spite of large doses of parenteral glucose replacement. On administration of somatostatin analogue octreotide, hypoglycemia resolved and, blood glucose levels were maintained even after cessation of parenteral glucose. The patient received 2 subcutaneous doses of octreotide 12 hours apart, and made a complete recovery. Our experience suggests that use of octerotide to treat refractory or prolonged sulfonylurea-included hypoglycemia in renal failure patients is safe and effective; large prospective studies would be needed to validate these findings.
Nzerue
C M
CM
Department of Medicine, Renal Section, University of Rochester School of Medicine, Rochester, NY 14642, USA. cmnzerue@aol.com
Thomas
J
J
Volcy
J
J
Edeki
T
T
D000328:Adult; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005913:Glipizide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D012640:Seizures / Q000209:etiology
D002096:C-Peptide; D005765:Gastrointestinal Agents; D007004:Hypoglycemic Agents; D015282:Octreotide; D005913:Glipizide